Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C

Hepatology Research

Volumn 40, Issue 12, 2010, Pages 1155-1167

  Chayama, Kazuaki ^a   Hayes, C Nelson ^a   Yoshioka, Kentaro ^b   Moriwaki, Hisataka ^c   Okanoue, Takeshi ^d   Sakisaka, Shotaro ^f   Takehara, Tetsuo ^e   Oketani, Makoto ^g   Toyota, Joji ^h   Izumi, Namiki ⁱ   Hiasa, Yoichi ^l   Matsumoto, Akihiro ^m   Nomura, Hideyuki ⁿ   Seike, Masataka ^o   Ueno, Yoshiyuki ^p   Yotsuyanagi, Hiroshi ^j   Kumada, Hiromitsu ^k  

^a HIROSHIMA UNIVERSITY   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

^c GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

^e OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g KAGOSHIMA UNIVERSITY   (Japan)

^h Sapporo Kosei General Hospital   (Japan)

ⁱ MUSASHINO RED CROSS HOSPITAL   (Japan)

^j UNIVERSITY OF TOKYO   (Japan)

^k TORANOMON HOSPITAL   (Japan)

^l EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^m SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ Shin Kokura Hospital   (Japan)

^o OITA UNIVERSITY   (Japan)

^p TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Combination therapy; Core protein; Genotype 1b; Interferon sensitivity determining region; Low density lipoprotein cholesterol

Indexed keywords

ALANINE AMINOTRANSFERASE; CORE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEGINTERFERON; RIBAVIRIN;

ADULT; AGE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; COMBINATION CHEMOTHERAPY; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 78649892926     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00726.x     Document Type: Article

References (58)

1. Barrera J, Bruguera M, Ercilla M et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995; 21: 639-44.
2. Niederau C, Lange S, Heintges T et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28: 1687-95.
3. Kiyosawa K, Sodeyama T, Tanaka E et al. Interrelationship of blood-transfusion, non-A, non-B hepatitis and hepatocellular-carcinoma - analysis by detection of antibody to hepatitis-C virus. Hepatology 1990; 12: 671-5.
4. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology 2004; 39: 5-19.
5. Suzuki T, Aizaki H, Murakami K, Shoji I, Wakita T. Molecular biology of hepatitis C virus. J Gastroenterol 2007; 42: 411-23.
6. Hadziyannis S, Sette HJ, Morgan T et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
7. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
8. Jensen DM, Marcellin P, Freilich B et al. Re-treatment of patients with chronic Hepatitis C who do not respond to peginterferon-alpha 2b a randomized trial. Ann Intern Med 2009; 150: 528-40.
9. Enomoto N, Sakuma I, Asahina Y et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis-C virus 1b - sensitivity to interferon is conferred by amino-acid substitutions in the NS5A region. J Clin Invest 1995; 96: 224-30.
10. Enomoto N, Sakuma I, Asahina Y et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81.
11. Yen YH, Hun CH, Hu TH et al. Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin. Aliment Pharmacol Ther 2008; 27: 72-9.
12. Akuta N, Suzuki F, Hirakawa M et al. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: Amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol 2009; 81: 452-8.
13. Hung CH, Lee CM, Lu SN et al. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin. J Viral Hepat 2003; 10: 87-94.
14. Hayashi K, Katano Y, Ishigami M et al. Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy. J Viral Hepat 2010.
15. De Rueda PM, Casado J, Paton R et al. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses. J Virol 2008; 82: 6644-53.
16. Berg T, Marques AM, Hohne M, Wiedenmann B, Hopf U, Schreier E. Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment. Hepatology 2000; 32: 1386-95.
17. MacQuillan GC, Niu XW, Speers D et al. Does sequencing the PKRBD of hepatitis C virus NS5A predict therapeutic response to combination therapy in an Australian population? J Gastroenterol Hepatol 2004; 19: 551-7.
18. Sarrazin C, Herrmann E, Bruch K, Zeuzem S. Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses. J Virol 2002; 76: 11079-90.
19. Jenke ACW, Moser S, Orth V, Zilbauer M, Gerner P, Wirth S. Mutation frequency of NS5A in patients vertically infected with HCV genotype 1 predicts sustained virological response to peginterferon alfa-2b and ribavirin combination therapy. J Viral Hepat 2009; 16: 853-9.
20. Layden-Almer JE, Kuiken C, Ribeiro RM et al. Hepatitis C virus genotype 1a NS5A pretreatment sequence variation and viral kinetics in African American and white patients. J Infect Dis 2005; 192: 1078-87.
21. Vuillermoz I, Khattab E, Sablon E et al. Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy. J Med Virol 2004; 74: 41-53.
22. Puig-Basagoiti F, Forns X, Furcic I et al. Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C. J Gen Virol 2005; 86: 1067-75.
23. Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 2007; 20: 23-38.
24. El-Shamy A, Sasayama M, Nagano-Fujii M et al. Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pre-treatment sera. Microbiol Immunol 2007; 51: 471-82.
25. El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology 2008; 48: 38-47.
26. Yang SS, Lai MY, Chen DS, Chen GH, Kao JH. Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin. Liver International 2003; 23: 426-33.
27. Akuta N, Suzuki F, Sezaki H et al. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2006; 78: 83-90.
28. Akuta N, Suzuki F, Kawamura Y et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: Amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46: 403-10.
29. Okanoue T, Itoh Y, Hashimoto H et al. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol 2009; 44: 952-63.
30. Mori N, Imamura M, Kawakami Y et al. Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic Hepatitis C: correlation between Amino acid substitutions in the Core/NS5A region and virological response to interferon therapy. J Med Virol 2009; 81: 640-9.
31. Ishii K, Shinohara M, Sawa M et al. Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of Hepatitis C virus genotype 1 showing substitution of Amino acid 70 in the core region. Intervirology 2010; 53: 105-10.
32. Larrea E, Garcia N, Qian C, Civeira MP, Prieto J. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 1996; 23: 210-17.
33. Reiberger T, Aberle JH, Kundi M et al. IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection. Antivir Ther 2008; 13: 969-76.
34. Romero-Gomez M, Viloria MD, Andrade RJ et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-41.
35. Zografos TA, Liaskos C, Rigopoulou EI et al. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic Hepatitis C. Am J Gastroenterol 2008; 103: 605-14.
36. Welzel TM, Morgan TR, Bonkovsky HL et al. Variants in interferon-alpha pathway genes and response to pegylated interferon-alpha2a plus ribavirin for treatment of chronic Hepatitis C virus infection in the Hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 2009; 49: 1847-58.
37. Hijikata M, Ohta Y, Mishiro S. Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon. Intervirology 2000; 43: 124-7.
38. Knapp S, Yee L, Frodsham A et al. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun 2003; 4: 411-19.
39. Matsuyama N, Mishiro S, Sugimoto M et al. The dinucleotide microsatellite polymorphism of the IFNAR1 gene promoter correlates with responsiveness of hepatitis C patients to interferon. Hepatol Res 2003; 25: 221-5.
40. Naito M, Matsui A, Inao M et al. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C. J Gastroenterol 2005; 40: 381-8.
41. Tsukada H, Ochi H, Maekawa T et al. A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C %J. Gastroenterology 2009; 136: 1796-805, e6.
42. Ge DL, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
43. Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
44. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
45. Thomas DL, Thio CL, Martin MP et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
46. Charlton MR, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. Hepatology 2006; 43: 1177-86.
47. Gopal K, Johnson TC, Gopal S et al. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 2006; 44: 335-40.
48. Guidi M, Muratori P, Granito A et al. Hepatic steatosis in chronic hepatitis C: impact on response to anti-viral treatment with peg-interferon and ribavirin. Aliment Pharmacol Ther 2005; 22: 943-9.
49. Bergmann JF, Vrolijk JM, Van Der Schaar P et al. g-Glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders. Liver Int 2007; 27: 1217-25.
50. Sezaki H, Suzuki F, Kawamura Y et al. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci 2009; 54: 1317-24.
51. Kogure T, Ueno Y, Fukushima K et al. Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan. World J Gastroenterol 2008; 21: 7225-4230.
52. Watanabe S, Enomoto N, Koike K et al. Prolonged treatment with pegylated interferon alpha 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan. Hepatol Res 2010; 40: 135-44.
53. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis - diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
54. Akuta N, Suzuki F, Hirakawa M et al. Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin. J Med Virol 2010; 82: 575-82.
55. Izopet J, Payen JL, Alric L et al. Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy. J Med Virol 1998; 54: 86-91.
56. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 31: 1426-32.
57. Izumi N, Enomoto N, Uchihara M et al. Hepatic iron contents and response to interferon-alpha in patients with chronic hepatitis C. Relationship to genotypes of hepatitis C virus. Dig Dis Sci 1996; 41: 989-94.
58. Syed GH, Amako Y, Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab 2010; 21: 33-40.